Dare Bioscience Financials - Benzinga

Dare Bioscience Inc

DARENASDAQ

Trade with Public

Trade with Public

$1.42

0.08996.76%

Last update: Aug 7, 2:00 PM

Earnings: Q2 2026 Earnings in 6 days from now on Thu Aug 13th, after the market close

Conference Call: Conference call scheduled in 6 days at 4:30 PM

Click to view the webcast

Overview News Earnings Forecast EventsFinancialsSentiment Ownership Compare Stock Report

Dare Bioscience Financials

Dare Bioscience (DARE) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Dare Bioscience Q1 EPS $(0.20) Beats $(0.27) Estimate, Sales $152.455K Miss $984.667K Estimate

Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.27) by 25.93 percent. This is a 60 percent increase over losses of $(0.50) per share from the

Benzinga Newsdesk

Earnings Scheduled For May 14, 2026

Benzinga Insights

PRO
Dare Bioscience Q4 EPS $(0.02) Beats $(0.43) Estimate, Sales $1.024M Beat $375.750K Estimate

Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.43) by 95.37 percent. This is a 96.92 percent increase over losses of $(0.65) per share from

Benzinga Newsdesk

Earnings Scheduled For March 26, 2026

Benzinga Insights

PRO
Dare Bioscience Q3 EPS $(0.28) Beats $(0.39) Estimate, Sales $2.262K Miss $9.750K Estimate

Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.39) by 27.27 percent. This is a 49.09 percent increase over losses of $(0.55) per share from

Benzinga Newsdesk

Earnings Scheduled For November 13, 2025

Benzinga Insights